Biorchestra

BIORCHESTRA is an innovative biotech company focused on the research and development of ribonucleic acid (RNA) based therapeutics for neurodegenerative diseases. The company's mission is to shift the therapeutic paradigm from symptom management to fundamental cures for conditions including Alzheimer's and Parkinson's diseases. BIORCHESTRA specializes in RNAi, mRNA, and novel drug delivery systems targeting central nervous system (CNS) diseases, with active programs in early diagnostics and clinical development. The company has offices at One Kendall Square in Cambridge, Massachusetts, and at its founding location in Daejeon, South Korea, and actively seeks global R&D and commercialization partners. Founded in 2016 by Dr. Branden Ryu, BIORCHESTRA has participated in high-level state diplomatic engagements, reflecting the strategic importance of its pipeline.